---
document_datetime: 2023-09-21 17:00:28
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/chondrocelect-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: chondrocelect-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.813177
conversion_datetime: 2025-12-29 19:54:17.775056
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ChondroCelect

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------|-----------|
| IAIN/0012/G          | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder product | 14/10/2014                                                                       | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                 |            |            |                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0009  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                  | 26/06/2014 | 22/08/2014 | SmPC, Annex II, Labelling and PL longer | Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit-risk balance of ChondroCelect remains positive, but considers that post-marketing experience with respect to patient number and duration of follow-up is still quite limited, and doesn't warrant granting a renewal with unlimited validity. Therefore one additional renewal application should be submitted in 5 years' time. Due to the strong influence of hormones on ossification, cartilage formation and repair and the limited experience in patients below 18 years ChondroCelect was contraindicated in patients with a femoral epiphyseal growth plate that is not fully closed. authorised |
| IA/0008 | B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test product                                                                                                                                                                                                        | 12/11/2013 | n/a no     |                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0007 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                            | 11/11/2013 | 22/08/2014 | Annex II and PL                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0006 | to add a new manufacturing site for ChondroCelect drug product and to submit results from user testing of package leaflet. B.II.b.2.b.3 - Change to batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and one of the test methods is a biol/immunol/immunochemical Medicinal | 20/09/2012 | 24/10/2012 | Annex II and PL                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | method                                                                                                                                                                                                                                                                                                          |            |            |                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------------------|
| IB/0004   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                      | 24/05/2012 | 24/10/2012 | SmPC, Annex II, Labelling and PL authorised |
| IA/0005   | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                      | 07/05/2012 | n/a        |                                             |
| IB/0002   | B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer                                                                                                 | 10/11/2011 | n/a        | longer                                      |
| IA/0003/G | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system product | 29/09/2011 | n/a no     | SmPC and Annex II                           |
| II/0001   | Changes to the manufacturing process of the active substance. B.I.d.1.b.2 - Stability of AS - Change in the storage conditions - Change in storage conditions of biological/immunological ASs, when the stability studies have not been performed in accordance with a Medicinal                                | 17/02/2011 | 02/03/2011 |                                             |

<div style=\"page-break-after: always\"></div>

| currently approved stability protocol   |
|-----------------------------------------|

Medicinal product no longer authorised